

## Highlights of the 8th Annual Conference of the ISPOR Italy Rome Chapter

The 8th Annual Conference of the ISPOR Italy Rome Chapter was successfully held in Rome, November 28-29, 2022 with about 180 in-presence participants from national and regional authorities, health care organizations, academic institutions, consulting agencies and manufacturers of drugs and medical devices.

The Conference was endorsed by AIES (Italian Association of Health Economists), CEIS (Centre for Economic Studies, Tor Vergata), SiHTA (Italian HTA Society) and UPO (Piemonte Orientale University).

Among experts and governmental officials: Dr Mauro Biffoni, Director of the Department of Oncology and Molecular Medicine, National Institute of Health (ISS) and member of AIFA Technical Scientific Commission (CTS); Dr Valentino Confalone, from the Presidential Committee of Farmindustria (Italian Association of Pharmaceutical Industry); Dr Fabrizio Gemmi, Coordinator of the Observatory for Quality and Equity, Regional Health Agency Tuscany; Dr Patrizia Popoli, President - AIFA Technical Scientific Commission, Director National Centre for Research and Preclinical and Clinical Evaluation of Medicines, Istituto Superiore di Sanità (ISS); Dr Pierluigi Russo, Director - AIFA Offices of Economic Evaluations and Monitoring Registers; Dr Giovanna Scroccaro, President - AIFA Price and Reimbursement Committee, Director Drug&Devices Dept, Veneto Region.

The conference was held as a plenary meeting, articulated over 5 sessions, each of them structured around lectures, discussions and round-tables.

At the opening ceremony, Pier Luigi Canonico (President) welcomed participants and introduced the Sessions; Andrea Marcellusi (President- Elect) presented the ISPOR projects completed during 2022.

SESSION I moderated by F. Luccini and M. Mezzetti (ISPOR Rome Chapter Directors) was aimed at reporting the “State of the art on the use of economic evaluations in P&R Dossiers, in Italy”, after about 18 months from the enforcement of the new Dossier structure and Guidelines issued in late 2020 by AIFA. Participation of P. Russo and G. Scroccaro from AIFA, together with F. Damele as a representative of the industry and P. Berto of the consulting business, was extremely appreciated by participants as it prompted a very interesting discussion on how economic analyses contribute to the approval of pharmaceuticals, how this contribution is valued by the Italian Regulatory Agency and how it could evolve and could be improved in the future.

SESSION II was moderated by P.L. Canonico and R. Samele and was focused on “Dynamic Reimbursement and indication-based pricing” with contributions from Industry representatives, F. Paternello (AstraZeneca) and M. Dobрева (Sanofi) and the illustration by C. Jommi of an ISPOR Rome Chapter Working Group Report “PRICE AND REIMBURSEMENT IN THE CASE OF INDICATION EXTENSION” which also included the results of a survey among ISPOR Rome Chapter members on the topic. A Report on the WG conclusion will soon be published on our website.

SESSION III was moderated by P. Berto (ISPOR Rome Chapter Director) and A. Marcellusi (President-Elect) and was aimed at presenting and discussing another new ISPOR Rome Chapter document entitled “GOOD PRACTICES FOR THE DEVELOPMENT OF BUDGET IMPACT MODELS AT REGIONAL LEVEL”. The document was produced by a group of ISPOR Members coordinated by A. Marcellusi, and supported by a Steering Committee composed of representatives from government institutions, academia, consulting agencies and manufacturers. Three of the ISPOR members who contributed to the document (S. Mucherino, M. Ferrario and A. Bortolami) together with Prof Marcellusi, described the contents and a group of experts discussed the findings and the conclusions in the following highly participated round table. The full document can be accessed at <https://www.isporitaly.org/index.php/documenti>

As a conclusion of day 1, participants enjoyed Poster viewing and networking at the wine & cheese reception, in the best ISPOR tradition.

Day 2 started with the special SESSION on Podium Presentations moderated by P. Berto and G. Zapparelli, in which the most interesting and relevant abstracts submitted by Chapter members were presented and discussed. In total 21 abstracts were received, all of them accepted as Poster presentations; 5 were selected as Oral presentations from +35yrs members and 5 from -35yrs members.

SESSION VI was focused on Real World Evidence and was introduced and moderated by P.L. Canonico and A. Pierini (ISPOR Rome Chapter Director). M. Ferrario and A. Marcellusi illustrated another ISPOR Rome Chapter document: “REAL WORLD EVIDENCE TO SUPPORT PRICE AND REIMBURSEMENT EVALUATION PROCESSES IN ITALY”. Discussants were P. Popoli and M Biffoni from AIFA/ISS, P Russo from AIFA and M. Zibellini from Farindustria. The document can be accessed at <https://www.isporitaly.org/index.php/documenti>

SESSION V was dedicated to the recently founded GIRF (ISPOR ROMA FOR FUTURE GROUP) a group of young ISPOR members (age<35yr). R. Viti and S. Mucherino presented the Group’s activities and introduced the 2nd GIRF Congress to be held in Milano in May 2023 with the coordination of C. D’Avella (Sanofi). This session also included 5 Podium Presentations from young ISPOR/GIRF members: all of them were extremely focused and well-presented and were applauded by the large audience.

At the end of the Conference' sessions, recipients of the Research Presentation Podium and Poster Awards were communicated: M. Soro for best Podium presentation of "Real-world data analysis of clinical outcomes and economic impact for the management of patients with chronic kidney disease with and without secondary hyperparathyroidism in an Italian population panel" and G. M. Pistillo for best Poster presentation of "Newborn screening for spinal muscular atrophy in Italy: economic and policy analysis".

Finally, the ISPOR Rome Chapter General Assembly was held to inform all members of the achievements of the Association during 2022: sponsorships (6 sponsors plus 4 premium sponsors), free-membership for members under 30 years of age, enlarged membership with 341 members in total (of which 103 members under 35yr), future initiatives and programs.